ThalidezineCAS# 18251-36-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 18251-36-0 | SDF | Download SDF |
PubChem ID | 320711 | Appearance | Powder |
Formula | C38H42N2O7 | M.Wt | 638.74 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(CCN6C)C(=C(C(=C7O3)OC)OC)O)OC)OC | ||
Standard InChIKey | UYNHKOIUEXICNQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C38H42N2O7/c1-39-15-13-24-20-31(43-4)33-21-27(24)28(39)17-22-7-10-25(11-8-22)46-32-19-23(9-12-30(32)42-3)18-29-34-26(14-16-40(29)2)35(41)37(44-5)38(45-6)36(34)47-33/h7-12,19-21,28-29,41H,13-18H2,1-6H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Thalidezine, a novel AMPK activator, eliminates apoptosis-resistant cancer cells through energy-mediated autophagic cell death. 2. Thalidezine can inhibit the growth of mouse L1210 cells in vitro. 3. Thalidezine possesses antimicrobial activity against Mycobacterium smegmatis at concentrations of 100 microgram/ml or less. |
Targets | AMPK | Autophagy | Antifection |
Thalidezine Dilution Calculator
Thalidezine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.5656 mL | 7.8279 mL | 15.6558 mL | 31.3116 mL | 39.1396 mL |
5 mM | 0.3131 mL | 1.5656 mL | 3.1312 mL | 6.2623 mL | 7.8279 mL |
10 mM | 0.1566 mL | 0.7828 mL | 1.5656 mL | 3.1312 mL | 3.914 mL |
50 mM | 0.0313 mL | 0.1566 mL | 0.3131 mL | 0.6262 mL | 0.7828 mL |
100 mM | 0.0157 mL | 0.0783 mL | 0.1566 mL | 0.3131 mL | 0.3914 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SB 225002
Catalog No.:BCC8077
CAS No.:182498-32-4
- TPMPA
Catalog No.:BCC6903
CAS No.:182485-36-5
- Lomitapide
Catalog No.:BCC5570
CAS No.:182431-12-5
- Rupatadine Fumarate
Catalog No.:BCC4535
CAS No.:182349-12-8
- Baldrinal
Catalog No.:BCN2667
CAS No.:18234-46-3
- Antibiotic 2158
Catalog No.:BCN1825
CAS No.:182320-34-9
- Antibiotic ZG 1494alpha
Catalog No.:BCN1850
CAS No.:182320-33-8
- Synthalin sulfate
Catalog No.:BCC6730
CAS No.:182285-12-7
- Lirioprolioside B
Catalog No.:BCN2740
CAS No.:182284-68-0
- Clausine I
Catalog No.:BCN4687
CAS No.:182261-94-5
- 3,4-seco-Olean-12-en-4-ol-3,28-dioic acid
Catalog No.:BCN7151
CAS No.:182249-69-0
- Nyssoside
Catalog No.:BCN1146
CAS No.:182138-70-1
- (9Z,12Z)-N-Benzyloctadeca-9,12-dienamide
Catalog No.:BCN1518
CAS No.:18286-71-0
- Dibritannilactone B
Catalog No.:BCN7776
CAS No.:1829580-18-8
- Valepotriate
Catalog No.:BCN2351
CAS No.:18296-44-1
- Didrovaltrate
Catalog No.:BCN7124
CAS No.:18296-45-2
- 3,4-O-Isopropylidene shikimic acid
Catalog No.:BCN1147
CAS No.:183075-03-8
- Fabiatrin
Catalog No.:BCN2920
CAS No.:18309-73-4
- Cabazitaxel
Catalog No.:BCC4966
CAS No.:183133-96-2
- Guanylin (human)
Catalog No.:BCC7204
CAS No.:183200-12-6
- Tipiracil hydrochloride
Catalog No.:BCC2001
CAS No.:183204-72-0
- 1,7-Dihydroxy-2,3-methylenedioxyxanthone
Catalog No.:BCN7543
CAS No.:183210-63-1
- AM251
Catalog No.:BCC4412
CAS No.:183232-66-8
- 2-Acetoxy-3-deacetoxycaesaldekarin E
Catalog No.:BCN7476
CAS No.:18326-06-2
[Anti-tumor effect of hernandezine and other components extracted from Thalictrum glandulosissimum].[Pubmed:2284950]
Yao Xue Xue Bao. 1990;25(5):330-5.
The total alkaloids of T. glandulosissimum and its main component hernandezine were found to be effective for treatment of mice bearing P388 leukemia, S180 ascites and C26 colon cancer. Although hernandezine inhibited the growth of mouse L1210 cells and human oral cancer KB cells in vitro markedly, its inhibitory effect on normal hemopoietic progenitor cells (CFU-GM) in mice was relatively low. Preliminary results showed that hernandezine blocked cell-cycle transfer from G1 to S phase, and its cytocidal action might be cell cycle specific. In addition, two other components, Thalidezine and isoThalidezine, isolated from the same plant exerted similar inhibitory effect on L1210 cells.
Alkaloids of Thalictrum. XXI. Isolation and characterization of alkaloids from the roots of Thalictrum podocarpum.[Pubmed:331006]
Lloydia. 1977 Jul-Aug;40(4):384-94.
Thirteen alkaloids, hernandezine, Thalidezine, N-desmethylThalidezine, isoThalidezine, thalistyline, thalistyline methodiiodide, N-desemethylthalistyline, berberine, columbamine, jatrorrhizine, palmatine, thalifendine, magnoflorine and the artifact, 8-trichloromethyldihydroberberine were isolated from the roots of Thalictrum podocarpum Humb. In addition, oxyberberine and thaliglucinone were obtained in very minor amounts and identified by tlc. Of these compounds, N-desmethylThalidezine and isoThalidezine are new bisbenzylisoquinoline alkaloids. Sucrose was isolated from the alcoholic extract. Hernandezine, thalistyline, Thalidezine, thalistyline methodiiodide and N-desmethylthalistyline were found to possess antimicrobial activity against Mycobacterium smegmatis at concentrations of 100 microgram/ml or less.
Thalidezine, a novel AMPK activator, eliminates apoptosis-resistant cancer cells through energy-mediated autophagic cell death.[Pubmed:28404910]
Oncotarget. 2017 May 2;8(18):30077-30091.
Cancers illustrating resistance towards apoptosis is one of the main factors causing clinical failure of conventional chemotherapy. Innovative therapeutic methods which can overcome the non-apoptotic phenotype are needed. The AMP-activated protein kinase (AMPK) is the central regulator of cellular energy homeostasis, metabolism, and autophagy. Our previous study showed that the identified natural AMPK activator is able to overcome apoptosis-resistant cancer via autophagic cell death. Therefore, AMPK is an ideal pharmaceutical target for chemoresistant cancers. Here, we unravelled that the bisbenzylisoquinoline alkaloid Thalidezine is a novel direct AMPK activator by using biolayer interferometry analysis and AMPK kinase assays. The quantification of autophagic EGFP-LC3 puncta demonstrated that Thalidezine increased autophagic flux in HeLa cancer cells. In addition, metabolic stress assay confirmed that Thalidezine altered the energy status of our cellular model. Remarkably, Thalidezine-induced autophagic cell death in HeLa or apoptosis-resistant DLD-1 BAX-BAK DKO cancer cells was abolished by addition of autophagy inhibitor (3-MA) and AMPK inhibitor (compound C). The mechanistic role of autophagic cell death in resistant cancer cells was further supported through the genetic removal of autophagic gene7 (Atg7). Overall, Thalidezine is a novel AMPK activator which has great potential to be further developed into a safe and effective intervention for apoptosis- or multidrug-resistant cancers.